The Food and Drug Administration is requiring a new warning label on GLP-1 weight-loss and diabetes medications covering a rare condition that can cause sudden, possibly permanent vision loss in one eye.
FDA adds vision-loss warning to all GLP-1 drugs including Ozempic and Wegovy
The Food and Drug Administration is requiring a new warning label on GLP-1 weight-loss and diabetes medications covering a rare condition that can cause sudden, possibly permanent vision loss in one eye.
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.